The company believes that Hanlon's leadership experience, background in accounting and finance, and strategic vision will help Federated Hermes continue to serve its clients and enhance shareholder value, as well as support its global growth and innovation efforts.
Market participants hold the company in high regard due to its five-year earnings growth track record. The recent sell-off could be an opportunity, worth checking for signs of long term growth.
Investors' doubts about Federated Hermes, Inc.'s future earnings seem reflected in its low P/E ratio, signaling reluctance to pay more for the stock given expected limited growth. A near-term surge in share price appears unlikely.
The slower EPS growth compared to the share price growth suggests that the market holds the company in higher regard currently. The high TSR indicates that dividends paid by Federated Hermes have boosted the total shareholder return.
Federated Hermes股票討論區
專欄Top upgrades and downgrades on 6/29: MSFT, UPST, MCD, GS and more
• $鏗騰電子(CDNS.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $175 (from $160)
•$Federated Hermes(FHI.US)$ : KBW Upgrades to Outperform from Market Perform - PT $540
•$高盛(GS.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $380 (from $360)
• $麥當勞(MCD.US)$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $278 (from $245)
• $甲骨文(ORCL.US)$ : Exane Upg...
專欄Today's pre-market stock movers: CRWD, CAH, DPZ, CSCO and more
• $Actinium(ATNM.US)$ +30.81% (Actinum Pharma and Immedica to commercialize lomab-B (1311 apamistamab) in Europe the Middle East and North Africa)
• $Aeglea BioTherapeutics(AGLE.US)$ +18.11% (presents additional data from PEACE phase 3 study of Pegzilarginase; submits BLA to FDA for Pegzilarginase)
• $Grid Dynamics(GDYN.US)$ +5% (expands in Europe ceases operations in Russia)
• $Artisan Partners Asset Management(APAM.US)$ +4....
暫無評論